Actinium Pharmaceuticals is a late-stage biopharmaceutical company focused on developing radiotherapies for AML patients. The company's leading product candidate, Iomab-B, has shown promising ...
Revenue: US$94.2m (down 8.3% from 1Q 2023). Net income: US$27.7m (down 23% from 1Q 2023). Profit margin: 30% (down from 35% in 1Q 2023). EPS: US$0.83 (down from US$1.08 in 1Q 2023). All figures ...
Actinium : Iomab-B Phase 3 Trial Results Show Significant Survival Benefit In High-Risk AML Patients
(RTTNews) - Actinium Pharmaceuticals Inc. (ATNM) said that median overall survival of 5.49 months observed in patients with a TP53 mutation receiving an Iomab-B led allogeneic bone marrow ...
- KOL and principal investigator, Dr. Farrukh Awan, Professor of Medicine, Division of Hematology Oncology at University of Texas Southwestern to join Actinium management on the webinar - Webinar to ...
Actinium : Iomab-B Phase 3 Trial Results Show Significant Survival Benefit In High-Risk AML Patients
(RTTNews) - Actinium Pharmaceuticals Inc. (ATNM) said that median overall survival of 5.49 months observed in patients with a TP53 mutation receiving an Iomab-B led allogeneic bone marrow ...
CHICO, Calif. (AP) — CHICO, Calif. (AP) — TriCo Bancshares (TCBK) on Thursday reported first-quarter profit of $27.7 million. The Chico, California-based bank said it had earnings of 83 cents ...
Tuesday - Actinium Pharmaceuticals, Inc. (NYSE:ATNM) received a new Overweight rating from Stephens, accompanied by a $25.00 price target. The biopharmaceutical company, specializing in ...
CHICO, Calif. (AP) — CHICO, Calif. (AP) — TriCo Bancshares (TCBK) on Thursday reported first-quarter profit of $27.7 million. The Chico, California-based bank said it had earnings of 83 cents ...
TriCo (TCBK) came out with quarterly earnings of $0.83 per share, beating the Zacks Consensus Estimate of $0.81 per share. This compares to earnings of $1.07 per share a year ago. These figures ...
TriCo (TCBK) came out with quarterly earnings of $0.83 per share, beating the Zacks Consensus Estimate of $0.81 per share. This compares to earnings of $1.07 per share a year ago. These figures ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback